IPO Profile: Histogenics Corp

Company Details

Waltham, Mass.

781-547-7900

www.histogenics.com

Description: Histogenics Corporation develops tissue regeneration to combines cell therapy and tissue engineering technologies. The company develops and manufactures products that improve the body’s ability to regenerate healthy cartilage, improve joint function and prevent degenerative disease. The company offers VeriCart, an auto-regenerative cartilage matrix; and NeoCart, an autologous engineered neocartilage. It also develops new treatments for sports injuries and other orthopedic conditions.

IPO Details

Exchange and Ticker: Nasdaq: HSGX

Filing Range: 4.29 million shares @ $13.00 to $15.00

Offering Price: $11.00

Close price as of 12/11/14): $8.66

Offering Size: $65.00M

Shares Outstanding: 12.4M

Underwriters: Cowen

Needham & Co

Canaccord Genuity Corp

Co-manager: BTIG

Company Counsel: Gunderson Stough Villeneuve Franklin

Manager Counsel: K&L Gates

Auditor: Grant Thornton LLP

Market Capitalization on 12/31/14: $109.91M

Close price on 12/31/14: $8.85

Investment Details

Venture Backers:

• Foundation Medical Partners
• Boston Millennia Partners
• Sofinnova Ventures Inc
• Split Rock Partners
• FGI Capital Partners Inc
• Inflection Point Ventures
• Undisclosed Firms

Financing Rounds:

• 8/1/06 $13.1M
• 9/4/08 $13.1M
• 5/11/10 $34.3M
• 6/11/10 n/a
• 9/9/10 n/a
• 11/9/10 n/a
• 2/18/11 n/a
• 5/11/11 $34.3M
• 11/15/11 n/a
• 3/12/12 n/a
• 7/27/12 $37.4M
• 11/21/12 $0.15M
• 12/18/13 $10.3M
• 5/27/14 $5.2M

Source: Data provided by Thomson Reuters.